// App-Quantinova.ai

4332 : Discovery of BAY 1163877 - A pan-FGFR inhibitor: De novo structure-based design and lead optimization of benzothiophenyl-pyrrolotriazines

Researchers

Presenter

  • Marie-Pierre L. Collin

Principal Investigators

  • Mario Lobell

  • Walter Huebsch

  • Dirk Brohm

  • Melanie Heroult

  • Klemens Lustig

  • Sylvia Gruenewald

  • Ulf Boemer

  • Rolf Jautelat

  • Holger Hess-Stump

  • Stefan Jaroch

  • Michael Brands

  • Karl Ziegelbauer

Medical Centers

  • Bayer HealthCare, Wuppertal, Germany

  • Bayer HealthCare, Berlin, Germany.

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • BAY-1163877

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved